Martina Garau

Office of Health Economics

12 Whitehall

London, SW1A 2DY

United Kingdom

SCHOLARLY PAPERS

9

DOWNLOADS

353

CITATIONS

3

Scholarly Papers (9)

1.

Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries

OHE Briefing, No. 52, October 2009
Number of pages: 32 Posted: 27 Aug 2015
Martina Garau and Jorge Mestre-Ferrandiz
Office of Health Economics and Office of Health Economics
Downloads 110 (245,155)

Abstract:

Loading...

2.

Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?

Number of pages: 7 Posted: 25 Aug 2015
Martina Garau, Adrian Towse and Patricia M. Danzon
Office of Health Economics, Office of Health Economics and University of Pennsylvania - Health Care Systems Department
Downloads 79 (303,546)
Citation 1

Abstract:

Loading...

3.

Multi-Criteria Decision Analysis to Value Orphan Medicines

OHE Research Paper 13/03
Number of pages: 29 Posted: 15 Aug 2015 Last Revised: 17 Aug 2015
RAND Europe, GSK, Office of Health Economics, GlaxoSmithKline, Rare Diseases and Independent
Downloads 74 (315,372)

Abstract:

Loading...

4.

Estimating Pharmaceutical Companies’ Value to the National Economy - Case Study of the British Pharma Group

OHE, February 2007
Number of pages: 20 Posted: 27 Aug 2015
Martina Garau and Jon Sussex
Office of Health Economics and RAND Europe
Downloads 28 (471,135)

Abstract:

Loading...

5.

Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

OHE Research Paper 12/03
Number of pages: 27 Posted: 19 Aug 2015
Office of Health Economics, Office of Health Economics, University of Washington, University of Washington and Novartis Institutes for Biomedical Research - Novartis Pharma AG
Downloads 19 (520,915)
Citation 1

Abstract:

Loading...

6.

Exploring the Interdependencies of Research Funders in the UK

Number of pages: 161 Posted: 16 Aug 2015 Last Revised: 24 Oct 2015
Office of Health Economics, RAND Europe, Office of Health Economics, Office of Health Economics, SPRU (Science Policy Research Unit), University of Sussex, University of Sussex, University of Sussex, University of Sussex, SPRU (Science Policy Research Unit) - University of Sussex, Science Policy Research Unit (SPRU), University of Sussex - Science and Technology Policy Research Unit (SPRU), University of Sussex - Science and Technology Policy Research Unit (SPRU), University of Sussex - Science and Technology Policy Research Unit (SPRU) and University of Sussex - Science and Technology Policy Research Unit (SPRU)
Downloads 18 (526,732)
Citation 1

Abstract:

Loading...

7.

Using QALYs in Cancer: A Review of the Methdological Limitations

Number of pages: 28 Posted: 22 Aug 2015
Office of Health Economics, Office of Health Economics, University of York, Independent, Office of Health Economics and University of York - Centre for Health Economics
Downloads 14 (550,050)
Citation 2

Abstract:

Loading...

8.

Is the Link between Health and Wealth Considered in Decision Making? Results from a Qualitative Study

Number of pages: 20 Posted: 16 Aug 2015
Martina Garau, Koonal Shah, Priya Sharma and Adrian Towse
Office of Health Economics, Office of Health Economics, United States Agency for International Development (USAID) and Office of Health Economics
Downloads 11 (568,184)

Abstract:

Loading...

9.

Modelling the R&D Process for Global Diseases Driven By Public-Private Partnersips (PPPs)

iHEA 2007 6th World Congress: Explorations in Health Economics Paper
Posted: 07 Jul 2007
University of Nottingham, Office of Health Economics, Office of Health Economics, Office of Health Economics, University of Oxford - Department of Public Health - Health Economics Research Centre (HERC) and Office of Health Economics

Abstract:

Loading...

Markov model, R&D process, global diseases

Other Papers (1)

Total Downloads: 0
1.

Donor Investment Choices in Developing Countries: A Methodology and Some Illustrative Results Based on Public-Private Partnerships for Product Development (PD PPPs)

iHEA 2007 6th World Congress: Explorations in Health Economics Paper
Posted: 09 Jun 2007
University of Oxford - Department of Public Health - Health Economics Research Centre (HERC), University of Nottingham, Office of Health Economics, Office of Health Economics and Office of Health Economics

Abstract:

Loading...

Cost-effectiveness frontiers, R&D process, global diseases, Product Development Public Private Partnerships